Patient-Derived Organoids for Drug Screening and Development
Dr. Sylvia Boj discusses the biology underlying organoids, how it contributes to their relevance as model systems and their use in drug discovery and precision medicine. During her postdoctoral fellowship in the lab of Dr. Hans Clevers, Dr. Boj generated and characterized a novel system for modeling pancreatic ductal adenocarcinoma using organoids grown from isolated pancreatic ducts. Now a Scientific Director at the Foundation Hubrecht Organoid Technology (HUB), Dr. Boj is involved in the characterization of organoid model systems with the goal of developing novel platforms for drug discovery. This approach has been successfully used at the HUB using patient-derived organoids to screen treatment outcomes in Cystic Fibrosis.
Publish Date:
July 25, 2017
Views: 0
Related Multimedia
-
Why Culture Intestinal Organoids with IntestiCult™ Organoid Growth Medium
Publish Date: January 22, 2015 -
From Stem Cells to Organoids: Modeling the Gastrointestinal Tract
Publish Date: June 20, 2014 -
Modeling Human Gastrointestinal Development and Disease Using Pluripotent Stem Cells
Publish Date: March 06, 2017
Explore Our Products
-
IntestiCult™ Organoid Growth Medium (Human)
Cell culture medium for establishment and maintenance of human intestinal organoids -
IntestiCult™-SF Organoid Growth Medium (Human)
Serum-free and conditioned medium-free cell culture medium for establishment and maintenance of human intestinal organoids -
STEMdiff™ Gastric Organoid Differentiation Kit
Culture medium kit for differentiation of human gastric organoids -
IntestiCult™ Organoid Differentiation Medium (Human)
Cell culture medium for further differentiation of human intestinal organoids in 3D, or as monolayers/air-liquid interface cultures
